Uncategorized Archives - Green Market Report

Dave HodesJuly 21, 2022
shutterstock_1198665856.jpg?fit=960%2C632&ssl=1

13min31

When a psychedelic substance gets to Phase 3 trials, like the one completed by the Multidisciplinary Association for Psychedelic Studies (MAPS) with MDMA in August 2021, there is a general sense of relief. It’s been a long journey from Phase 1 for most substances in a clinical trial process—up to four years for Phase 3 alone in some cases. And only 33 percent of experimental drugs move from Phase 2 to Phase 3.

But getting to Phase 3 signals an extra red alert for any psychedelic company working the process to get Food and Drug Administration (FDA) approval.

According to an investigative article in the Journal of the American Medical Association (JAMA) Internal Medicine, Phase 3 clinical trials provide the highest level of evidence that an experimental treatment is safe and efficacious. But many of these trials for investigational or experimental drugs like psychedelics, which typically involve large numbers of patients, and require substantial investment on the part of participants, investigators, and sponsors, fail at this stage. 

Only 25 to 30 percent of experimental drugs are approved by the FDA at this stage, and move out of Phase 3 to Phase 4 trials.

Using public sources and commercial databases covering drugs and biologics that started trials between 1998 and 2008, the investigative article reported that roughly half of investigational drugs entering late-stage clinical development fail during or after pivotal Phase 3 clinical trials, primarily because of concerns about safety, efficacy, or both. Results for the majority of studies of investigational drugs that fail are not published in peer-reviewed journals—just 8 percent, according to the JAMA investigative article, demonstrating a lack of information sharing that could cause other trials to waste time and resources if their trials use similar methodologies.

For psychedelics specifically, there is historical context for problematic clinical trials. Research on psychedelic drugs in psychiatry in the 1950s and 1960s was abandoned for a number of reasons, according to a research paper published by the National Institutes of Health (NIH). 

A major factor was that clinical research on psychedelic drugs was caught up in the tighter regulation of pharmaceutical research after the Thalidomide disaster in 1963. (Thalidomide was used to treat nausea in pregnant women, but was later discovered to create severe birth defects.)

Psychedelic drugs also presented special challenges for randomized, placebo-controlled clinical trials in the 1970s that were not as positive as the claims made by their advocates in the 1950s and 1960s. Clinical research became more difficult after 1965 when Sandoz ceased providing psychedelic drugs for research, and their nonmedical use was prohibited in 1970.

But, contrary to the usual narrative, the demise of psychedelic drug research was not solely due to the “War on Drugs.” The NIH research paper said that the demise of psychedelic research came about in part because of the pharmaceutical industry’s lack of interest in funding clinical trials.

All that changed around 2000, when psychedelic clinical trials started up again and, since then, have gained momentum especially over the last few years.

Now, there are 111 psilocybin clinical trials in some stage of development, the majority of them announced or begun between 2019 and 2022; 117 clinical trials with MDMA, with 17 announced or begun in 2022 alone; and 30 clinical trials of LSD.

But to be sure, there are still clinical trial difficulties. One recently withdrawn psilocybin study was ended because of violations of good clinical practices, or GCP. These could be violations of getting informed consent, adherence to protocol, or reporting of serious adverse events during the trial.

Another psilocybin study was withdrawn because the sponsor of the study changed. The study will be released, managed and registered by another institution who will be acting as a responsible party, according to the trial record.

There are a host of other reasons that a psychedelics clinical trial was terminated, including staff turnover, lack of funds, and insufficient patient population for study enrollment. 

Clinical trials have also failed in general because human subjects not responding to the drug the way that animal models do, or because of an insufficient understanding of how the investigational product interacts with the body.

Unexpected results from clinical trials can be devastating. One example: When Compass Pathways (NASDAQ: CMPS) announced their Phase 2b clinical trial with psilocybin for treatment resistant depression in November, 2021—the largest randomized, controlled, double-blind psilocybin therapy study ever completed.

The main issue? 12 patients out of 233 reported treatment-emergent serious adverse events (TESAE) that included suicidal behavior, intentional self-injury, and suicidal ideation.

The Compass Pathways stock declined significantly—as did some other psychedelic companies as news of the trial results rippled through the industry. Compass Pathways’ stock decline from the results of that September, 2021 trial continued through 2022 (though its showing signs of recovery today).

Psychedelics is helping drive more innovation when it comes to clinical trials. There are new ideas emerging in clinical trial structure for psychedelics. The FDA developed the “fast track” process to facilitate development and expedite review of drugs to fill an unmet need, such as psychedelics for PTSD. 

And there is a fairly new concept from the FDA’s critical path initiative in 2006 called the adaptive design clinical trial, defined as a design that allows modifications to the trial and/or statistical procedures of the trial after its initiation without undermining its validity and integrity.

The purpose is to make clinical trials more flexible, efficient and fast. 

Due to the level of flexibility involved, these trial designs are also termed as “flexible designs.” It is being used now by MAPS in their Phase 2 trials. That kind of design is common for drugs with limited investment (either because they are being developed by nonprofits, because they have limited revenue potential if approved, or for rare conditions).

Recent policymaking aimed at stimulating pharmaceutical innovation has focused on allowing drugs to be approved on the basis of smaller data sets, according to the JAMA investigative article. Some commentators have proposed waiving the need for phase 3 testing, although others

have responded that approval before rigorous study could worsen health outcomes by leading to widespread use of toxic or ineffective drugs that would have otherwise been shown to

have failed. “As many investigational products fail in late stage development because of inadequate efficacy or safety, our findings suggest that additional efforts to promote drug

development should be directed at improving the validity of preclinical models for use in translational research and increasing the number of innovative products entering trials,” the research article concluded. “The timely publication of trial results for all investigational agents,

including those that fail in late-stage clinical development, is imperative.”


Debra BorchardtJune 14, 2022
daily-hit.jpg?fit=700%2C394&ssl=1

6min10

The Daily Hit is a recap of the top cannabis business stories for June 13, 2022. Due to technical difficulties, we were unable to publish this recap yesterday.

ON THE SITE

High Times on the Hook for $5M in Back Rent

Harvest Health or rather Trulieve (OTC: TCNNF) since it bought Harvest Health must be heaving a sigh of relief that it’s High Times on the hook for the rent at Geary St. in San Francisco. Before it was acquired Harvest Health had tried to quickly jump into the San Francisco market by signing numerous agreements. One of them was with Alexis Bronson from the Have A Heart 2 CA LLC  as a social equity licensee for a dispensary at a prime shopping spot on the famous Geary Street. Read more here.

Ayr Wellness Kicks Off New Jersey Rec Sales this Week

Ayr Wellness (OTC: AYRWF) will kick off its adult-use sales in New Jersey this Wednesday June 16th at three dispensaries. Ayr’s adult-use dispensaries are in Woodbridge, Union, and Eatontown, all within Central New Jersey, a region of 3.4 million people. Ayr’s adult-use stores represent 3 of 5 adult-use stores in this highly populated region. Ayr currently operates its New Jersey dispensaries under the Garden State Dispensary banner. Read more here.

RIV Capital Preps for New York Adult Use Sales

RIV Capital Inc. (CSE: RIV) (OTC: CNPOF) reported its financial results for the fourth quarter and fiscal year ending March 31, 2022. For the fourth quarter Riv Capital reported a net loss of $17 million versus last year’s net loss of $21 million for the same time period. The company had an operating loss in the fourth quarter of $2 million. Riv said the loss was primarily driven by an increase in the provision for expected credit losses on interest and royalty receivables. Read more here. Read more here.

Measuring Psychedelic Investing Risk

Biotechnology is always a dicey business to create, run, and make profitable. Psychedelics add a difficulty factor of 10 to that equation. Currently, there are many psychedelic companies still working their compound through clinical trials—with no actual product to market and sell for years. Much of the real success of any psychedelic business hinges on the completion of clinical trials and Food and Drug Administration (FDA) approval, which takes serious time and money and is never guaranteed. Read more here.

IN OTHER NEWS

The Scotts Miracle-Gro Company Adds Brian Sandoval to Board

The Scotts Miracle-Gro Company (NYSE: SMG), marketers of branded consumer lawn and garden as well as hydroponic and indoor growing products, announced today that The Honorable Brian Sandoval has been named to its Board of Directors. Governor Sandoval served two terms as the 29th Governor of the State of Nevada, having held office from 2011 to 2019. He is currently the President of the University of Nevada, Reno, a position he has held since 2020. Read more here.

Chemistree Technology Inc.

Chemistree Technology Inc. (CSE: CHM) and (OTCQB: CHMJF), provided Notice of the semi-annual payment of interest on its convertible debentures maturing March 29, 2024.  Pursuant to the Supplemental Indenture entered into with the Debenture Trustee, Odyssey Trust Company, effective January 17, 2022, the Company will pay the interest due on June 30, 2022 – via the issuance of common shares in lieu of payment in cash. Read more here.


StaffFebruary 18, 2022
shutterstock_1376854163-1-scaled.jpg?fit=1200%2C825&ssl=1

16min00

Vertosa

Austin Stevenson, Chief Innovation Officer at Vertosa

 

When did you formally enter the cannabis space?

Well I’ve been consuming cannabis for much longer than I’ve been working in the industry…but I got involved in the ‘professional’ cannabis industry nearly a decade ago, when I was an advisor to an accelerator in agriculture technology in Africa. I went to the MIT Innovation Laboratory, and I saw African farmers cultivating green leafy vegetables in the middle of the Kalahari Desert, via hydroponic indoor cultivation in freight containers. Seeing this piqued my curiosity, so when I got back to the U.S. and put my detective hat on and learned that it was really the cannabis industry that was driving innovation in terms of indoor, vertical farming. At that point, I took it as an opportunity to dive in and get started, as an advisor at a cannabis accelerator in Colorado.

My cannabis career evolved from advising to investing, then operating different cannabis businesses. Immediately prior to joining Vertosa, I led the regulatory Hemp/CBD testing program for Eurofins Scientific – a world leader in food, environment, and product testing services – where I built and designed quality testing protocols for CVS Pharmacy and other retailers who carry Hemp/CBD products.

It was during my time at Eurofins that I really got to see the good, the bad and the ugly of infused products. I identified major inconsistency issues for product potency and stability, which I knew needed to be corrected for the industry to progress and succeed long term and of course to build consumer trust.

Serendipitously, around the same time an old friend, someone who I respected in the cannabis investing arena, now Co-Founder and Vertosa CEO Ben Larson, reached out to me. He said he has been working with a PhD scientist focused on applying his expertise in surface chemistry to creating emulsion systems to infuse beverages and topicals with cannabis, ensuring precise potency and consistently stable products. This turned out to be Vertosa Co-Founder and CSO Dr. Harold Han — he was correcting the major issues I identified in the infused products industry while working at Eurofins. I knew we had to work together to help solve these problems in the cannabis-infused products supply chain.

What made you decide to work in the cannabis industry?

People, Products, and IMPACT! I simply love designing new and innovative products and watching how they impact people. I am energized by collaborating with teams, debating ideas, learning from different perspectives, and nurturing relationships with my team and partners. There is an immense amount of joy I experience when I’m able to help someone take an idea and turn it into a real, tangible product which they can taste and feel!

Additionally, I feel the unique intersection between product innovation, and public policy drives my passion to participate in the cannabis and hemp industry. For years, consumers have been limited to traditional forms of cannabis (flower and hash oil). In the past, many consumers (including myself) have been forced to hide, and enjoy the healing properties of the plant in secrecy because of regulatory restrictions. We’re now in one of the most transformative time periods in the modern age. With smartphone technologies, the world’s vast knowledge database is literally at our fingertips. Science is leading new product innovation, and cannabis is legal and more accessible than ever. By combining knowledge, science, and access, we now have an opportunity to recreate the narrative and redefine how and why cannabis is used around the world.

As a result of legalization, new jobs, products, and opportunities are developing. But with great opportunity there is great responsibility. This is the reason why I am an advocate for equity grants, workforce development, and other private and public mechanisms to fund start-up businesses run by people of color and others impacted by the War on Drugs. This is also the reason WHY we at VERTOSA have designed an INNOVATION PLATFORM and are committed to GIVING VALUE AND EMPOWERING ALL ENTREPRENEURS that have an idea AND BRINGING IT TO LIFE!

Do you feel there is more opportunity for Black Americans in the cannabis industry versus a more traditional industry? Yes or no and why?

Growing up my mother always said, “nothing in life will just be given to you, especially because being Black in America means you’ll need to work twice as hard for the same opportunity”. To that end, I feel that there is no real difference in the amount of opportunities for Black Americans in the cannabis industry versus traditional industries. In fact there may be fewer, because of the many barriers to entry which the cannabis industry imposes: economic barriers, organizational barriers like nepotism, regulatory barriers, the list goes on…

Yet, we all know this is a once in a generation opportunity to be a part of something as great as standing up a new industry – regardless of your race. So I am reminded of Dr. Martin Luther King Jr.’s famous quote, “[we] will not be judged by the color of [our] skin but by the content of [our] character”.

Reminded of those famous words by Dr. King, and my Mother’s encouraging words, we as Black Americans must continue to work hard to create the opportunities we deserve. Personally, I believe the best way to do that is to lead by example. I AM driven to serve others, and am most passionate about economic empowerment for the communities I serve. Since my days in microfinance, empowering other BIPOC and women entrepreneurs is my reason WHY. As industry builders, we are also job-creators, and with a positive intention to create more opportunities for all, we have the opportunity to create more jobs and opportunities to lift each other up!  As a result, we may truly “be the change [we] see in the world”. That’s why I am so grateful to my co-founders, who share the belief that we must first build a company that is the best place to work in the cannabis industry. With that positive intention at the beginning, we now have one of the most diverse teams in the cannabis industry, and are continuing to create more opportunities for others to join us in our mission to unlock the healing power of the cannabis plant, and make it more approachable and accessible to all!

 What is the most successful social equity effort in your opinion? Can be a charity or company program.

It’s too early to validate any effort as successful. In many states equity programs are just now starting to be built, and there is still a long road ahead. What I will say is collaboration is the new competition and we have an opportunity to start a movement that calls out cannabis operators who prioritize profit over people and products. The cannabis industry is as diverse as the country we live in. It is full of amazing leaders who are people of color, women, LGBTQ, and other minorities. However, many of the cannabis products on retailers’ shelves today are not made or representative of this diverse community that the space intends to serve. Instead, those who have always benefited from privilege continue to benefit in the burgeoning industry, and the privilege gap will continue to widen unless we create a movement that helps amplify the voices of BIPOC, Women, LGBTQ, and Minority entrepreneurs. So what’s the solution / path forward?

First, we can use consumer advocacy groups to demand current cannabis brands/manufacturers to donate a percentage of revenue to sponsor grants for minority cannabis entrepreneurs. This is something I’m personally supporting as an Advisor for EAZE’s Momentum Program.

Second, we can use local and state regulatory programs to create equity awards and licenses for underserved minority populations. This is another initiative that I am supporting as a Member of the City of Oakland’s Cannabis Regulatory Commission.

Third, those that ‘have’ must ‘give’. Companies who are profiting off cannabis today must ‘give-back’. If it’s not through grant funding, then by supporting an equity license for a minority to start their own company. Then ‘give’ job training and internship opportunities to all those that have been convicted of a non-violent marijuana crime. Re-entry programs for those whose lives were turned upside down from this plant, which is now a multi-billion-dollar industry, is an immediate opportunity to ‘right’ many of the ‘wrongs’.

Vertosa is helping these initiatives through our work with the Last Prisoner Project, EAZE Momentum, and Our Dream. In summary, profiteering only exacerbates inequality. Grants, Equity Licenses, and Job Training are requirements to create a more equitable cannabis industry. Professionals in the industry have a responsibility to re-write history by leading by example and creating an inclusive, equitable, and diverse cannabis community. By applying pressure at the national, state, and local levels, we have an opportunity to rise and shine together!

What is your personal goal for 2022?

Goal setting is core to who I am, so I have many personal and professional goals for myself this year. The purpose of goals is to set a target and achieve it; or to identify a problem, and solve it. Reflecting on myself, one challenge that I have been faced with is ‘perfectionism’. Too many times, I’ve let my desire to be perfect get in the way of progress. So the one (1) personal goal which I remind myself every single day when I look in the mirror (it’s literally written on a post-it on the mirror) is a quote from Lorenzo Snow, “Do not expect to become perfect at once. If you do, you will be disappointed. Be better today than you were yesterday, and be better tomorrow than you are today.” Thus, I am confident that if I am constantly striving to be better than I was the previous day, that I will accomplish all that I set out to achieve.


StaffNovember 17, 2021
stockmarket.jpg?fit=960%2C576&ssl=1

4min00

Poseidon Investment Management announced the launch of the AdvisorShares Poseidon Dynamic Cannabis ETF (Ticker: PSDN). The PSDN ETF began trading on Wednesday, November 17, 2021, is sponsored by AdvisorShares. It will be sub-advised and managed by the Poseidon team, including co-founders and Managing Directors Emily Paxhia and Morgan Paxhia and Managing Director Tyler Greif. Poseidon is one of the earliest cannabis investing teams that has $196 million in assets under management as of August 2021. 

“Poseidon was one of the first investment firms dedicated to cannabis investments, navigating this complex and evolving industry to help companies grow and thrive from startups to public companies,” said Emily Paxhia, co-founder and Managing Director of Poseidon, and Portfolio Manager of PSDN. “Our track record speaks to our deep knowledge of the space and our commitment to understanding the needs of the companies we invest in. PSDN broadens the reach of our unique investment philosophy and provides simple, secure, accessible investing into one of the world’s most exciting asset classes.”

ETF’s Have Underperformed

Poseidon will have their work cut out for them. Cannabis ETF’s have mostly underperformed this year as the underlying stocks have been wallowing in a seeming never ending bear market. AdvisorShares Pure US Cannabis ETF (Ticker: MSOS) reached a year high of $55 but was lately selling shares at $30, while AdvisorShares Pure Cannabis ETF (Ticker: YOLO)  hit a year’s high of $31 and was recently selling its shares at $16. The Cannabis ETF (THCX) also topped out this year at $30 and was lately selling at $12 a share.

Poseidon said that the fund will try to identify companies strategically positioned to benefit from the cannabis industry and its supporting infrastructure in the U.S. and emerging global cannabis markets. PSDN’s portfolio is diversified across subsectors of the cannabis industry and dynamically managed to tactically overweight or underweight specific countries, subsectors, or individual companies. PSDN said it may seek to take advantage of specific market opportunities by intelligently using leverage to maximize potential returns. If the values of the underlying stocks start to recover, the PSDN’s timing could be quite good.

“We are excited to partner with an established and experienced team like Poseidon to bring their institutional portfolio management approach into the mainstream investment infrastructure,” said Noah Hamman, chief executive officer of AdvisorShares. “Active ETFs in the cannabis space continue to gain traction with investors seeking to access managers with proven success records in the fast-growing, dynamic industry.”

 


StaffJuly 28, 2021
David-McCullough-6178-crop-1.jpg?fit=755%2C753&ssl=1

6min30

Prior to being appointed CTO of Akerna, David McCullough served as Akerna’s Executive Vice President of Product & Engineering, overseeing all software development, development operations, quality assurance, automations, systems, and security operations. He has 16 years of Software Engineering experience. Before joining Akerna, he was the CTO of StudentPublishing.com, where he actively managed the technical aspects of Student Publishing’s sale to and systems integration with lulu.com. David has extensive government systems experience and was also a professor at New Mexico State University where he taught courses in data communications and networking. 

 

GMR Executive Spotlight Interview Q & A:

 

Title:

Chief Technology Officer (CTO)

Company:

Akerna

Years at current company:

Six

Most successful professional accomplishment before cannabis:

Before David’s work in cannabis, he invented an online self-publishing software that allows schools and children to create and publish books online to be published as physical books and returned to the writer.

Company Mission:

We are passionate about solving problems that better our world. Akerna provides data-driven cannabis solutions worldwide across the entire cannabis supply chain. Our technology empowers the cannabis industry to prove outcomes that positively change lives every day.

Company’s most successful achievement:

Our CEO, Jessica Billingsley, co-founded the company that invented seed-to-sale tracking in 2010. This was done upon identifying the need for organic material tracking and compliance SaaS solutions in the nascent cannabis industry. We recognized that due to the unique complexities and needs of the industry, cannabis needed technology built for it specifically, not just adapted from other industries. We believed visibility across the entire supply chain from seed-to-sale would be a requirement for the industry’s sustained growth. Today, this type of tracking is a requirement of most states that regulate legal cannabis.

In 2017, we launched MJ Platform, the cannabis industry’s first ERP in response to the maturing of the cannabis market to multi-state enterprise businesses. We also led international expansion in the cannabis technology sector very early on in 2012 in Canada then into Spain. Today, our total footprint spans 23 states and 15 countries. Innovation and seeing what opportunities are next on the horizon – and then being ready for them first – has been a hallmark of Akerna since the inception of our flagship product MJ Freeway.

In 2019, Akerna became the first cannabis software business to be traded on a major U.S. exchange, Nasdaq (ticker KERN). This listing was an unprecedented milestone for the cannabis industry and signified a shift in beliefs and generated ripples of opportunity for the future of the industry.

Since then, we have grown the Akerna family to include many leading cannabis and alcohol technology solution s: Ample Organics,  Last Call Analytics,  Leaf Data Systems,  MJ Freeway/MJ Platform, solo sciences, Trellis, and Viridian Sciences.

Today,  Akerna is the cannabis industry’s only scaled technology provider, enabling compliance, regulation, and taxation. We provide the single most comprehensive product ecosystem for cannabis operators that have businesses across any part of the supply chain, from seed-to-sale. This provides transparency and accountability along virtually every piece of the supply chain.

Over the past decade, we have seen much change in the political and social environments surrounding cannabis. As we prepare for a post-legalization landscape and the industry continues to consolidate and mature, we firmly believe the enterprise capabilities we offer, including comprehensive compliance solutions and financial reporting integrations, will become increasingly crucial to the future leaders of the cannabis industry.

Has the company raised any capital (yes or no): 

Yes

If so, how much?

Since going public Akerna has raised $22,000,000

Any plans on raising capital in the future?

 We feel we are well capitalized today and continue to have institutional support and access to the markets should the need arise.  We are always carefully evaluating the needs of the business to maximize long-term shareholder value. 

Most important company  5  year  goal:

To be the dominant provider of technology to the cannabis, hemp, and CBD industries, while also serving additional verticals by providing complete accountability and transparency to what consumers are putting in and on their bodies.


StaffJuly 22, 2021
cbd5.jpg?fit=960%2C506&ssl=1

6min11

Editors Note: This is a guest piece.

Cannabidiol oil is a by-product derived from the cannabis plant commonly known as CBD oil. It is manufactured to relieve pain, reduce anxiety and depression, alleviate cancer-related symptoms, and lessen acne. Generally, it is produced on a large scale in oil companies. The process of manufacturing CBD oil involves a huge amount of electricity. Due to the large amounts of energy usage, the oil companies have to pay costly energy bills. 

Thus, with this article, we tried to suggest some of the ways through which we can reduce energy bills and save electricity. Here are 5 ways using which you can save electricity while manufacturing CBD oil.

1) USING LED LIGHT

Normally 18 to 20 hours of lighting per day is required for growing cannabis. The operators who grow cannabis use high-pressure sodium lights which help to supplement sunlight during cold weather. This can be replaced by using LED lighting which is more efficient and will use up to 50 percent less energy as compared to the high-pressure sodium lights. Thus, LED recessed lighting from  https://www.lepro.com/led-recessed-lighting is a better alternative that will save electricity and also reduce electricity bills.

 

2) REDUCING HEAT AND DEHUMIDIFICATION

If we reduce the heat that comes from lighting, then it can reduce the load on the HVAC equipment by altering the humidity levels. Dehumidification is important for growing cannabis which requires mechanical cooling. Small cultivators may consider high-efficiency split ductless air conditioning and heat pump units which will consume less fan energy than the rooftop units. On the contrary, large cultivators may go with the chilled water system. This will lead to more potential energy savings.

 

3) GREENHOUSES

Greenhouses can save much more energy required per pound of cannabis than typical indoor cultivation. Since sunlight is used as an energy source for a greenhouse, this leads to a large reduction in energy consumption and saves electricity because there is a reduced need for artificial lighting. 

The indoor grow operations require more amount of artificial light during the vegetative stage and flowering stage as compared to the amount of supplemental artificial lighting needed by Greenhouses. Moreover, greenhouses allow more air circulation which will reduce the need for efficient fans and save electricity. Thus, Greenhouses are a preferable option to conserve electricity. 

 

4) ENERGY MANAGEMENT

The CBD oil companies should install smart and sophisticated meters from LEPRO to measure the baseline energy usage and demand. It would become easier to determine peak usage hours. Cultivators should prefer an energy audit of the operation by simple calculations. One should record total electricity consumption per pound of cannabis on a fortnightly or monthly basis. One should set targets to reduce energy consumption and implement a plan to save electricity and reduce energy usage.

You should also take the benefit of free energy audits and suggestions for improvement of the cannabis cultivation scheme offered by many energy companies. 

 

5) USE OF TECHNOLOGY

Technology will be proved as a boon if we use it in a systematic way for preserving electricity in CBD oil production. Firstly, we have to make the cannabis cultivators familiar with the utility of energy efficiency programs and services offered these days. One should choose well-qualified contractors (for cooling and dehumidification) with expertise in mechanical systems for CBD oil manufacturing. One can also have an integrated climate control system that is chosen by the cultivators best suited for their produce. Multi-output or variable speed equipment is also recommended for less power consumption. Additionally, these types of equipment prevent plant shock by not going from off to high setting.

 

CONCLUSION

These are some of the methods which can be used to reduce the power consumption needed in CBD oil production. As responsible citizens, we must save electricity and preserve it for future generations because sources of electricity are likely to exhaust if continued to be used at this high pace. Moreover, there is a link between energy use and the environment. If we consume less power, then we help to reduce the number of toxic gases released in the air by such oil companies and conserve our ecosystems from destruction.


StaffJuly 20, 2021
shutterstock_1061719172-scaled.jpg?fit=1200%2C800&ssl=1

7min00

In October 2017 Marijuana Business released the results of a survey on women in the cannabis industry. The survey found that women held 37% of executive-level roles in the cannabis industry. This was a milestone that women throughout the industry celebrated with excitement and promise as many women leaders began to plot the path to achieving 50% in five years. 

These numbers were used to encourage women across the country to leave their traditional, corporate jobs and find a place where they could contribute their skills to the growing industry. The high gains made activists believe that women really could hold power in a lucrative and dominating industry. The numbers inspired women to apply for licenses and open ancillary businesses, hoping to be among those benefiting from such strong industry support. 

The bubble burst in August 2017 when Marijuna Business announced those numbers had dropped to 27%. It was still considered a win as U.S. business as a whole women only comprise 24% of executive positions. But it wasn’t a win, it was a sting and it reverberated throughout the community. Women started leaving cannabis faster than they were coming in. 

Then came another blow. A Vangst survey in 2019 revealed only 17.6% of women surveyed held a Director or Executive Role. 2020 took women in the U.S. out of the workforce in droves and now one in four is considering not returning to work. It isn’t just the cannabis industry that is suffering a loss of female talent.

The future’s looking grim for those women still working in cannabis. In March 2021 Benzinga released a report saying that only 8% of CEOs in cannabis are women! Women are truly losing ground in cannabis…fast. 

So what are women supposed to do about this loss of power? How do they stop this power drain from continuing? How bad can it get if it isn’t stopped? What incredible opportunity are they protecting if they get in and fight for it? 

Power, as defined by Merriam-Webster, is the possession of control, authority, or influence over others. Possessing power, pursuing power and craving power are all seen through this lens, an exercise of influence over others. This can be unsettling or intimidating for women and can make them hesitant to hold onto power or wield it effectively. 

Another definition of power is a source or means of supplying energy. If we view it through this lens we see it as our flow of energy contributing to the creation of the industry. It isn’t just about having influence, per se, but having a consistent and strong flow of energy filling the cannabis industry – from women. This is how women will create the industry they have dreamt of since 2017. 

One of the most effective tools women have to create more power is Collaboration or working together for a common goal. Merriam-Webster defines it as: To cooperate with an agency or instrumentality with which one is not immediately connected. 

Collaboration is full of challenges. From personality clashes, to broken promises, and failed expectations, working with others is full of pitfalls. It’s also the key to creating a power source that has an impact. If women align themselves for a common purpose, to Pay, Promote, Partner & Protect one another, their power or energy source will be strong and undeniable in the industry. 

The Women Empowered in Cannabis (WEIC) Leadership Summit: Power & Collaboration will be taking a deep dive into the power dynamics and collaboration challenges along the cannabis supply chain. While it’s easy to see from the statistics from a top level it’s not as obvious how these power losses are occurring throughout the industry. Examining the unique dynamics on each part of the supply chain and shining a light on them is the first step in taking back the power women have lost over the last few years.

For more information on the WEIC Leadership Summit: 

https://www.eventhi.io/event/womens-leadership-summit-power-and-c-4810

 


StaffJuly 15, 2021
Harvest.jpg?fit=1200%2C800&ssl=1

4min10

Harvest Health & Recreation Inc.  (OTCQX: HRVSF) is done with Utah and expanding its Florida footprint. Harvest said it had completed the divestiture of its cultivation and processing operations in Utah for what it described as an immaterial amount of cash. The company said that a local operator bought the cultivation and processing operations located in Ogden, Utah. Following the sale, Harvest no longer has operations in Utah.

“We are pleased to have completed this divestiture as part of our strategic plan,” said Chief Executive Officer Steve White. “We will continue to allocate resources to growth opportunities in our core markets.” With that said, Harvest then announced the opening of a new medical dispensary in South Miami Beach, Florida.

“We are thrilled to open our eleventh Harvest location in Florida, one of the fastest-growing medical markets in the U.S.,” said White. “We look forward to serving patients and providing quality products at this new location in one of our core markets.”

Additional Harvest dispensaries in Florida are located in GainesvilleJacksonvilleKissimmeeLehigh AcresLongwoodNorth Miami BeachNorth Port, Olympia Heights, Tallahassee, and West Palm Beach.

Trulieve Buying Harvest

Trulieve announced in May that it was buying  Harvest Health in a deal valued at approximately $2.1 billion based on the closing price of the Trulieve Shares on May 7, 2021. The combined businesses will have operations in 11 states, comprised of 22 cultivation and processing facilities with a total capacity of 3.1 million square feet, and 126 dispensaries serving both the medical and adult-use recreational cannabis markets. In June, Trulieve said that the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 had passed.

Trulieve CEO Kim Rivers said, “Completion of the HSR milestone is exciting and we will continue to work toward closing this strategic transaction. Upon closing, we expect to leverage the expertise and resources of the combined companies to realize meaningful scale and expansion for years to come.”

The Harvest shareholder vote is expected to occur in the third quarter of 2021. Both companies say they continue to work toward obtaining all required regulatory approvals.

 


StaffJune 18, 2021
dab.jpg?fit=960%2C640&ssl=1

8min20

Editors Note: This is a guest post.

Do you know the difference between Dab Rig and Dab Pen? Let us start with what they are and what they are used for. By the way, a dab is a slang name for a wax puff using either a Dab Rig or Pen.

Dab Rings and Dab Pens are used for vaporizing wax concentrates to bring about an effect of high to the user. In essence, wax is this marijuana product that is quickly coming up especially among the youth. Since wax looks and feels like any of the hundreds of brands of lip balm brands, it is easily carried in lip balm containers

Although a product of marijuana, wax is much more concentrated; so much so that a puff of wax gives a kick or high equivalent to smoking like twenty joints of marijuana! Imagine that.

Naturally, some dabbers like Dab Pens while others prefer Dab Rigs. Each carries its weight and each has its lighter side, but experienced dabbers will prefer to own both.

A Dab Rig

Dab Rigs are very popular as this set-up of glass apparatus that dabbers use to sit around and smoke wax. It has several compartments; a mouthpiece, a small dish called a nail for putting the wax in and water carrying container. A Dab Rig is easily available from most smoke shops and especially nyvapeshop.com.

Pros

  • . A Dab Rig is loud, but most dabbers prefer it as its kick is like a thunderstorm. One puff from a rig simply takes the dabber by storm and sends them where they want to go.
  • . Dabbing Nails of Rigs are made of non-melt materials like titanium, ceramic, quartz, and even glass.
  • . They do not rely on electricity, so even during a power outage or a blackout, dabbers are still on top of their game.
  • . Dab rings have percolators with thick glass for a more advanced hit
  • . They have good grips which make their handling is more efficient.
  • . The container is re-usable without the prospect of needing service or replacement soon.

Cons

  • . Dab Rigs are bulkier and cumbersome if they have to be carried around.
  • . They are louder than the Dab Pen but much more fun for their users

The Dab Pen

Like the Rig, Dab Pens do the job of vaporizing the wax. They are mostly self-contained with all their features parked together. They are smaller in size than the Rig and are easily portable. They come in varying sizes, colors, and costs. They contain heating chambers with in-built coils that when heated, in turn, heat the wax and vaporize it for the dabber to puff.

Pros

  • . They are smaller than the Dab Rig in size and are easily portable
  • . For those who need discretion, they are better if they have to be carried around
  • . They don’t need a blow-torch or smoke to vaporize the wax.
  • . They are quieter and less loud than the Dab Rig
  • . The container is reusable for a long time without needing any extra service.

Cons

  • . Dab Pens use electricity. Sadly, for them, in case of a blackout, thunderstorm, hurricane, a hailstorm knocking down the power-line, or anything that interferes with electricity, Dab Pen users have to cut short their need for a high.
  • . The kick-in of a Dab Pen puff is not quite as powerful as that of a Dab Rig. It’s lower in power and seasoned dabbers prefer a Dab Rig puff to a Dub Pen one.
  • . Although easier to carry around, dabbers prefer a hit in a comfortable sitting position as opposed to moving around.

Similarities

Both dabs are for use in vaporizing wax for a puff.

Both have a variety of features to provide for every taste.  They are also available at varied prices in varied locations and outlets. There are very affordable ones and very expensive ones, plus everything in-between.

Their heating areas have thick bottoms made from either ceramics, glass, aluminum, or quartz for a non-melt effect.

They both give a high quite unlike previous uses of marijuana.

The Verdict

People’s tastes vary, from those who want a portable dab to those who want something powerful. Some dabbers may prefer something beautiful and sleek while others go for invisible and discreet. Still, others want something loud and visible.

The bottom line is the reason for the dab equipment. If it is for a good, powerful hit-you-like-an-ox high, the Dab Rig wins this case hands down. Moreover, when it is for something all season, come rain shine or blackout, my money is still on the Dab Rig.

However, if you need something quiet, no smoke, and electrically charged, you could go for the Dab Pen. The ball is in your court.

 


StaffJune 16, 2021
delivery-scaled.jpg?fit=1200%2C1200&ssl=1

8min20

Editors Note: This is a guest post.

Canada consists of many great things making it one of the world’s greatest countries where many would love to live. With the recent legalization of recreational marijuana, that list only got longer.

Weed delivery in Vancouver makes our lives a bit simple, and we just love the idea of getting our stash to our doorstep without the hassle of going out to shop searching.

Smoking weed became even more interesting, and many love the option of ordering some of the best-quality marijuana and other THC products such as edibles, oils, tinctures, vapes, and concentrates. 

The future generations will never know the struggle we had to go through every time we wanted to get our stash from a local dealer and risk legal consequences.

Now you might ask, what makes these delivery services in Vancouver so attractive?

Here are a few things making a big difference nowadays.

One-day deliveries

One of the top talking points nowadays is same-day weed deliveries that changed the way we order weed from dispensaries forever. People adore the option of getting their weed on the same day they’ve ordered it, and all dispensaries will likely look for a way to add this option to their business.

When considering the location where you live, some weed dispensaries in Vancouver can deliver your order in only a few hours, which was unimaginable in the past.

Have you ever thought that this day would come? Is this something we had all dreamed of back in the days?

One-day deliveries changed the way we get our weed, and hardly anything can happen to make us go back to the old ways when going out to a local dealer or store was the only way to get weed.

We got spoiled with online shopping services such as Amazon that offer fast deliveries to their premium users. Having the same option for weed only made online shopping even better.

Some suggest that going out to a local weed shop is out of the question, as postal services can do the hard part of going through high traffic instead of you.

A variety of products

Online weed shops in Vancouver offer many great THC products you can order through their mailing services.

Besides having the highest-quality marijuana strains in their offer, online shops will also sell everything weed-related. 

One of the most popular THC products nowadays are edibles, which made us go back to our childhood by resembling gummy bears. These edibles have a high concentration of THC and became favorites to all those trying to avoid smoking at any cost.

Enjoying marijuana without smoking is also possible by consuming products like concentrates or even vape juices. Having different options when ordering online popularized weed shops and made everyone happy to have services that will deliver some of the best weed in record time.

For those not into THC at all, these shops also offer many different CBD products they can use to improve their health if they are struggling with some issues like insomnia, lack of appetite, or even anxiety.

These products don’t have any THC, and everyone can use them regardless of their age.

The competition

One of the main reasons you have so many great options when buying weed online is the competition between the shops. Every shop nowadays has to have the best products to stand a chance in such a competition.

That’s all good news for us, as we can all get the best products available in only a few hours. Most shops look for a way to satisfy their customers, which is why we have same-day deliveries today.

The best from the best try to create new strains of weed and offer them to their customers that love different aromas or tastes. These shops are our heroes, and we love their dedication to create something we will all benefit from when buying their products.

As weed is now legal in Canada, we see a steady incline of new online shops that will create even stronger competition, and who knows, maybe some new and exciting products.

Healthy competition will always result in creating many new things we will all love. We can sit back, relax, and enjoy the ride these online shops will create for us. 

We can’t wait to see what the future holds for all of us loving marijuana and all of its products.

Conclusion

Weed delivery services help us save our precious time by excluding the necessity of going out to a local shop only to buy weed.

Everything we had to put any effort into in the past we can now do from the comfort of our homes, and there’s no reason to try to go back to old fashion ways.

Online shops are the future of weed shopping, especially with services such as same-day deliveries.

 


Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 5 hours

The Daily Hit: September 27, 2022

@GreenMarketRpt – 5 hours

Canadian Cannabis Giant Canopy Growth Quits Retail Game

@GreenMarketRpt – 6 hours

RT : Using your tax liability as creative financing … risky or effective? Check out this piece by @Johnschroyer

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.